Choosing the right cell line for renal cell cancer research

Table 1 Differentiation of RCC subtypes

Marker	Clear cell RCC	Papillary RCC Type 1	Papillary RCC Type 2	Chromophobe RCC	Oncocytoma	Xp11.2 translocation RCC
VHL mutation	+ (~90%)	-	-	-	-	-
cMET mutation	-	+	-	-	-	-
TP53 mutations	-	-	-	+	-	-
Other mutations	PBRM1 (~50%), BAP1 (~15%), SETD2 (~15%)	NRF2, CUL3	FH	-	Mitochondrial complex I genes	translocations of Xp11.2 (TFE3) or 6p21 (TFEB)
CK8	+/-	+	+	+/-	+	ND
CAIX	+	+/-	+	-	-	+
CAM 5.2	+	+	+	+	+	-
CD10	+	+	+	+/-	+/-	+
CD15	+	+	+	-	+	ND
CK18	+	+	+	+	+	ND
EMA	+	+	+	+	+	-
GST-alpha	+	-	-	-	-	ND
PAX2	+	+	+/-	-	+	+/-
PAX8	+	+	+	+	-	+
RCC Ma	+	+	+/-	-	-	+
VIM	+	+	+	-	-	+
AMACR	-	+	+	-	-	+
CD117	-	-	-	+	+	ND
CK7	-	+/-	-/+	+/-	-	+/-
CK19	-	-	-	-	-	+/-
CK20	-	-	-	-	-	-
c-KIT	-	+/-	+/-	+	+	ND
CLDN7/8	-	-	-	+	+	ND
E-cadherin	-	+	+/-	+	-	+
EpCAM	-	-	-/+	+	+/-	ND
Ksp-cad	-	-	-	-	+	+
PVALB	-	-	-	+	+/-	ND
TFE3	-	-	-	-	-	+
SMA	-	-	-	-	+	ND

Legend: AMACR α-methylacyl coenzyme A racemase, CAIX carbonic anhydrase IX, CK7 cytokeratin 7, CLDN7/8 claudin 7/8, EMA epithelial membrane antigen, GST-alpha glutathione S-transferase alpha, EpCAM epithelial cell adhesion molecule, Ksp-cad kidney-specific cadherin, PVALB parvalbumin, RCC Ma renal cell carcinoma marker, SMA smooth muscle action, TFE3 Transcription factor E3 - transcription factor binding to IGHM enhancer 3, PAX2/8 paired box gene 2/8, VIM vimentin, ND no reported data

ISSN: 1476-4598